The FDA's application record carries an action on NDA 022315, Ozurdex (dexamethasone intravitreal implant), sponsored by AbbVie. It is a supplement to an existing approval, and the record does not say what it covers.
There is no respiratory implication. Ozurdex is an intraocular corticosteroid implant used for macular oedema and posterior uveitis; the dose is delivered into the eye and this is not a systemic corticosteroid decision. It appears here because the regulatory sweep is not specialty-filtered, and reporting it plainly is better than dressing it up as respiratory news.
The only point of contact with a chest clinic is the general one: patients on repeated intraocular or systemic steroids for other conditions still need the usual attention to glycaemic control, bone health and infection risk, and that has not changed today.
- No action for respiratory practice - this is an intraocular corticosteroid implant
- Do not confuse an intravitreal implant with systemic steroid exposure when reviewing a drug chart
- Check the FDA label directly if a patient asks what the supplement covers
- The record does not address Ozurdex's Indian regulatory position
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free